| Q54649963 | A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. |
| Q96135356 | Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment |
| Q36746626 | Angiogenesis in cancer |
| Q51656262 | Angiogenesis inhibitors and hypoxia. |
| Q36636633 | Anti-VEGF therapy: a new approach to colorectal cancer therapy |
| Q35641618 | Antiangiogenic therapy and tumor progression |
| Q35109141 | Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response |
| Q35832193 | Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer |
| Q90349862 | Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms |
| Q28072166 | Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience |
| Q57247080 | Cancer cell adaptation to hypoxia involves a HIF‐GPRC5A‐YAP axis |
| Q35812538 | Cancer therapeutics: understanding the mechanism of action |
| Q33754109 | Capsaicin-induced activation of p53-SMAR1 auto-regulatory loop down-regulates VEGF in non-small cell lung cancer to restrain angiogenesis |
| Q93127591 | Clinical Significance of SERPINA1 Gene and Its Encoded Alpha1-antitrypsin Protein in NSCLC |
| Q57541456 | Cues for migration |
| Q34782774 | Drug development of MET inhibitors: targeting oncogene addiction and expedience |
| Q37145875 | Effect of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung cancer |
| Q35029884 | Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model |
| Q38081379 | Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer |
| Q81267790 | Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy |
| Q52653941 | Harnessing Biology to Deliver Therapeutic and Imaging Entities via Cell-Based Methods. |
| Q36834685 | Heat shock protein 90: the cancer chaperone |
| Q36066038 | Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update |
| Q38957511 | Heralding a new paradigm in 3D tumor modeling |
| Q34474687 | High therapeutic efficiency of magnetic hyperthermia in xenograft models achieved with moderate temperature dosages in the tumor area |
| Q43054130 | Histology-based expression profiling yields novel prognostic markers in human glioblastoma |
| Q41748943 | Hypoxia and Serum deprivation protected MiaPaCa-2 cells from KAI1-induced proliferation inhibition through autophagy pathway activation in solid tumors |
| Q90848321 | Hypoxia induced Sonic Hedgehog signaling regulates cancer stemness, epithelial-to-mesenchymal transition and invasion in cholangiocarcinoma |
| Q39655222 | Hypoxia inducible factor-1α expression in areca quid chewing-associated oral squamous cell carcinomas |
| Q55285319 | Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors. |
| Q33926474 | Hypoxic stress, hepatocytes and CACO-2 viability and susceptibility to Shigella flexneri invasion |
| Q90476391 | Imaging evaluation of sorafenib for treatment of advanced hepatocellular carcinoma |
| Q39456802 | Immune Priming of the Tumor Microenvironment by Radiation |
| Q38040787 | Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death |
| Q37349436 | Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition |
| Q37668231 | Inflammation and EMT: an alliance towards organ fibrosis and cancer progression |
| Q37004664 | Inhibition of angiogenesis and invasion in malignant gliomas |
| Q35966791 | Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer |
| Q28564217 | MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3 |
| Q36770262 | Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. |
| Q90455622 | New Directions in the Study and Treatment of Metastatic Cancer |
| Q38177753 | New treatments for bladder cancer: when will we make progress? |
| Q30471456 | Normalization of the vasculature for treatment of cancer and other diseases |
| Q92334728 | Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy |
| Q37296289 | Oxygen-mediated endocytosis in cancer |
| Q34375626 | REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. |
| Q37237705 | Radionuclide carriers for targeting of cancer |
| Q36394925 | Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists |
| Q35967197 | Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors |
| Q35104052 | Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities |
| Q35372584 | Targeted therapies for breast cancer |
| Q38110043 | Targeting molecular aberrations in urothelial carcinoma: are we almost there? |
| Q35751013 | Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia |
| Q82255367 | The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy |
| Q36428702 | Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited |
| Q90319010 | Tumor progression-dependent angiogenesis in gastric cancer and its potential application |
| Q38493162 | Tumorigenesis: cell defense against hypoxia? |
| Q38094627 | Tumour vasculature targeting agents in hybrid/conjugate drugs |
| Q35112894 | VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer |